These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36754346)

  • 1. Incretins play an important role in FFA4/GPR120 regulation of glucose metabolism by GW-9508.
    McKillop AM; Miskelly MG; Moran BM; Flatt PR
    Life Sci; 2023 Apr; 318():121475. PubMed ID: 36754346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc-induced activation of GPR39 regulates glucose homeostasis through glucose-dependent insulinotropic polypeptide secretion from enteroendocrine K-cells.
    Moran BM; Miskelly MG; Abdel-Wahab YHA; Flatt PR; McKillop AM
    Biol Chem; 2019 Jul; 400(8):1023-1033. PubMed ID: 30738010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
    Martinussen C; Veedfald S; Dirksen C; Bojsen-Møller KN; Svane MS; Wewer Albrechtsen NJ; van Hall G; Kristiansen VB; Fenger M; Holst JJ; Madsbad S
    Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E956-E964. PubMed ID: 32182123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
    Pathak V; Vasu S; Flatt PR; Irwin N
    Diabetes Obes Metab; 2014 Apr; 16(4):357-65. PubMed ID: 24164718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.
    McKillop AM; Moran BM; Abdel-Wahab YH; Gormley NM; Flatt PR
    Diabetologia; 2016 Dec; 59(12):2674-2685. PubMed ID: 27677765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the insulin-releasing and glucose-lowering effects of GPR120 activation in pancreatic β-cells.
    Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
    Diabetes Obes Metab; 2014 Nov; 16(11):1128-39. PubMed ID: 24919766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet.
    Hira T; Koga T; Sasaki K; Hara H
    Biochem Biophys Res Commun; 2017 Oct; 492(2):161-165. PubMed ID: 28803984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
    Pacini G; Thomaseth K; Ahrén B
    Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
    Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
    Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves.
    Mayer F; Gunawan AL; Tso P; Aponte GW
    Am J Physiol Gastrointest Liver Physiol; 2020 Jul; 319(1):G23-G35. PubMed ID: 32421358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
    Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
    Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA; Kerr BD; Harriott P; Flatt PR
    Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
    Ruetten H; Gebauer M; Raymond RH; Calle RA; Cobelli C; Ghosh A; Robertson RP; Shankar SS; Staten MA; Stefanovski D; Vella A; Wright K; Fryburg DA;
    Metab Syndr Relat Disord; 2018 Oct; 16(8):406-415. PubMed ID: 30117761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents.
    Moss CE; Marsh WJ; Parker HE; Ogunnowo-Bada E; Riches CH; Habib AM; Evans ML; Gribble FM; Reimann F
    Diabetologia; 2012 Nov; 55(11):3094-103. PubMed ID: 22872212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
    Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
    Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
    Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.